AURX · Nuo Therapeutics, Inc.
$1.14
+0.04 (+3.64%)
At close · Aug 31
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We believe based on the operating cash requirements and capital expenditures expected for the next twelve months that our current resources and projected revenue from sales of Aurix products and the Private Label product to Smith+Nephew are insufficient to support our operations for the next 12 months from the date these financial statements are issued. As such, we believe that substantial doubt about our ability to continue as a going concern exists.”View the 10-Q filed Aug 14, 2026
Market Cap
$53.28M
Shares
48.43M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| David E. Jorden | Chief Executive and Financial Officer | $225,000 |
| Peter A. Clausen | Chief Scientific and Operating Officer | $210,000 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| David E. Jorden | Chief Executive and Financial Officer | $225,000 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Peter A. Clausen | Chief Scientific and Operating Officer | $213,247 |
| David E. Jorden | Chief Executive and Financial Officer | $170,536 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| David E. Jorden | Chief Executive and Chief Financial Officer | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| David E. Jorden | Chief Executive and Chief Financial Officer | $55,112 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| David E. Jorden | Chief Executive and Chief Financial Officer | $140,543 |
| Peter A. Clausen | Chief Scientific Officer | $96,667 |